• Mabwell flagged Phase Ib/IIa results for anti-ST2 antibody 9MW1911 in moderate-to-severe COPD, slated for poster presentation at ERS 2026.
• Preliminary readout showed a favorable safety profile, with signals of fewer COPD exacerbations versus placebo at higher doses.
• Phase IIb enrollment in a larger COPD population has completed, setting up a Phase III start targeted for late 2026.
• FDA cleared an IND to run a Phase IIa COPD trial in the US, expanding the program’s development footprint.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mabwell (Shanghai) Bioscience Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609040900PR_NEWS_USPR_____CN40982) on September 04, 2026, and is solely responsible for the information contained therein.